National Health (Listed drugs on F1 or F2) Amendment Determination 2018 (No. 4) (PB 43 of 2018) (Cth)

PB 43 of 2018

National Health (Listed drugs on F1 or F2) Amendment Determination 2018 (No. 4)

National Health Act 1953

I, LISA LA RANCE, Assistant Secretary, Pricing and PBS Policy Branch, Technology Assessment and Access Division, Department of Health, delegate of the Minister for Health, make this determination under subsection 85AB(1) of the National Health Act 1953.

Dated        29  May 2018

LISA LA RANCE

Assistant Secretary

Pricing and PBS Policy Branch

Technology Assessment and Access Division

Department of Health

Part 1         Preliminary

1. Name of Determination

(1)   This Determination is the National Health (Listed drugs on F1 or F2) Amendment Determination 2018 (No. 4).

(2)   This Determination may also be cited as PB 43 of 2018.

1. Commencement

This Determination commences on 1 June 2018.

1. Amendment of National Health (Listed drugs on F1 or F2) Determination 2010

Schedule 1 amends the National Health (Listed drugs on F1 or F2) Determination 2010 (PB 93 of 2010).

Schedule 1             Amendments

(Section 3)

[1]     Schedule 1, after item dealing with Abiraterone

Omit

Acamprosate

[2]     Schedule 1, after item dealing with Adapalene with benzoyl peroxide

Omit

Adrenaline

[3]     Schedule 1, after item dealing with Budesonide

Omit

Buprenorphine

[4]     Schedule 1, after item dealing with Cabazitaxel

Insert

Cabozantinib

[5]     Schedule 1, after item dealing with Daclatasvir

Omit

Daclizumab

[6]     Schedule 1, after item dealing with Dexamphetamine

Omit

Didanosine

[7]     Schedule 1, after item dealing with Doxepin

Insert

Dulaglutide

[8]     Schedule 1, after item dealing with Enfuvirtide

Omit

Enoxaparin

[9]     Schedule 1, after item dealing with Etravirine

Omit

Everolimus

[10]   Schedule 1, after item dealing with Exenatide

Omit

Ezetimibe

[11]   Schedule 1, after item dealing with Interferon alfa-2a

Omit

Interferon alfa-2b

[12]   Schedule 1, after item dealing with Linagliptin

Omit

Lincomycin

[13]   Schedule 1, after item dealing with Minoxidil

Omit

Moxonidine

[14]   Schedule 1, after item dealing with Nivolumab

Insert

Nusinersen

[15]   Schedule 1, after item dealing with Soy protein and fat formula with vitamins and minerals – Carbohydrate free

Omit

Stavudine

[16]   Schedule 2, after item dealing with Abatacept

Insert

Acamprosate

[17]   Schedule 2, after item dealing with Adefovir

Insert

Adrenaline

[18]   Schedule 2, after item dealing with Budesonide with eformoterol

Insert

Buprenorphine

[19]   Schedule 2, after item dealing with Dorzolamide with timolol

Omit

Dothiepin

Insert

Dosulepin

[20]   Schedule 2, after item dealing with Enalapril with hydrochlorothiazide

Insert

Enoxaparin

[21]   Schedule 2, after item dealing with Etoposide

Insert

Everolimus

[22]   Schedule 2, after item dealing with Exemestane

Insert

Ezetimibe

Ezetimibe and rosuvastatin

Ezetimibe with simvastatin

[23]   Schedule 2, after item dealing with Levonorgestrel with ethinyloestradiol

Insert

Lincomycin

[24]   Schedule 2, after item dealing with Morphine

Insert

Moxonidine